Physician profile
David No
NPI 1366452658
$5,747.71
in general payments reported to CMS, 2019-2025
29 companies · $1,054 in 2025
The $1,054 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $602 · 2020: $236 · 2021: $559 · 2022: $835 · 2023: $1,183 · 2024: $1,278 · 2025: $1,054.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,320 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,320.48 |
| Education | $194.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,490.20 | 2021-2025 | |
| Genzyme Corporation | $748.49 | 2021-2025 | |
| Janssen Biotech, INC. | $490.03 | 2019-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $422.37 | 2019-2025 | Blu-U, Odomzo |
| Amgen INC. | $306.57 | 2019-2024 | Otezla |
| Galderma Laboratories, L.P. | $292.86 | 2019-2025 | Nemluvio, Aklief |
| Revance Therapeutics, INC. | $260.01 | 2024 | Daxxify |
| Novartis Pharmaceuticals Corporation | $257.90 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $229.76 | 2019-2025 | Dupixent |
| Arcutis Biotherapeutics, INC. | $169.99 | 2023-2025 | Zoryve |
| Allergan, INC. | $152.64 | 2019-2022 | |
| Lilly USA, LLC | $141.79 | 2019-2024 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $126.36 | 2019-2024 | |
| Incyte Corporation | $94.99 | 2023 | |
| Kerecis Limited | $85.16 | 2022-2024 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $66.85 | 2023-2024 | Vtama |
| Merz North America, INC. | $58.11 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $55.31 | 2022-2024 | Jublia |
| Leo Pharma INC. | $40.60 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $38.68 | 2020-2021 | |
| Organon LLC | $35.70 | 2025 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $35.70 | 2024-2025 | Sotyktu |
| Almirall LLC | $31.93 | 2019 | |
| Avanos Medical | $30.66 | 2019 | |
| Biofrontera INC. | $18.98 | 2020 | |
| Epi Health, LLC | $17.71 | 2019 | |
| Botanix Sb INC | $16.97 | 2025 | Sofdra |
| Dusa Pharmaceuticals, INC. | $16.11 | 2019 | |
| Ucb, INC. | $15.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David No listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.